Hexarelin - 2mg - Peptodio
Information based on published research
Growth

Hexarelin

2mg · 99%+ Purity

Description

CJC-1295 + Ipamorelin is a combination of a GHRH analog and a selective GH secretagogue, respectively, often studied together for sustained growth hormone release. Research focuses on their combined effects on muscle growth, fat loss, and recovery models. Each vial contains 5mg of each peptide.

Standard Dosage: 2mg

Disclaimer: The images on this page are for illustrative purposes only. Peptodio is an educational resource and does not sell any products, nor will we ever. We do not recommend or endorse any sellers or vendors. This information is provided for research and educational purposes only.

Research & Science

Evidence-based information about this compound

Chemical Properties

CAS Number

140703-51-1

Molecular Formula

C47H58N12O6

Molecular Weight

887.04 g/mol

Amino Acid Sequence

His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2

Also known as:

Examorelin, HEX

Hexarelin is a synthetic hexapeptide growth hormone secretagogue with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. It belongs to the Growth Hormone Releasing Peptide (GHRP) family and is considered one of the most potent GH secretagogues available.

Unlike natural GHRH, hexarelin acts through the ghrelin/GHSR receptor to stimulate growth hormone release. It produces a more robust GH response than other GHRPs but may have a more pronounced receptor desensitization effect with extended use.

Hexarelin has been studied for various applications including growth hormone deficiency, cardiac protection, and wound healing.

Hexarelin stimulates GH release through specific mechanisms:

  • GHSR Binding: Binds to the growth hormone secretagogue receptor (ghrelin receptor).
  • Pituitary Stimulation: Acts directly on pituitary somatotrophs to release GH.
  • Hypothalamic Effects: Also stimulates GHRH release from the hypothalamus.
  • IGF-1 Elevation: GH release leads to increased IGF-1 production.
  • Cardiac Effects: Has additional direct effects on cardiac tissue.

Hexarelin's GH-releasing effects have been well-characterized:

  • Potency: Produces among the strongest GH responses of any GHRP.
  • Dose Response: Shows clear dose-dependent GH elevation.
  • Comparison Studies: More potent than GHRP-6 and GHRP-2 in head-to-head comparisons.
  • Duration: Effects last approximately 4-6 hours post-administration.

However, hexarelin shows more receptor desensitization with chronic use than other GHRPs.

Hexarelin has shown unique cardioprotective properties:

  • Cardiac Binding: Binds to specific cardiac receptors independent of GH effects.
  • Ischemic Protection: Studies show protection against ischemia-reperfusion injury.
  • Contractility: May improve cardiac contractility.
  • Post-MI Effects: Research shows potential benefits in post-myocardial infarction models.

These cardiac effects are independent of GH release, suggesting direct cardiac activity.

This information is provided for educational purposes only and is based on published scientific research. This product is intended for research use only.

Research & Studies

Published research supporting the science behind this compound.